Intercept line of weight loss supplements shipping now to health, food, drug and mass outlets, firm announces at NACDS. Appetite Intercept contains ma huang, caffeine, tyrosine, phenylalanine; Ultra Carb Intercept contains 600 mg proprietary amylase inhibitor blend to "prevent carbohydrates from turning into fat"; and Ultra Chitosan Fat Intercept Plus, with 1,000 mg chitosan, "intercepts and passes fat through the digestive system before it can be absorbed," trade materials claim. A 30-count bottle of each product will carry a suggested retail price of $9.99. Magazine ads broke in June books. Separately, Natrol My Defense will hit health food store shelves at end of July. Immune-support product contains 1,500 mg arabinogalactan as ImmuneEnhancer AG, a patented ingredient from raw material supplier Larex (White Bear Lake, Minn.). Product "enhances natural killer cell activity," firm says. A 75-count bottle will sell for $23.99
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.
